Healthlynked Financials
This page shows Healthlynked (HLYK) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
HealthLynked’s main operating shift is a smaller cash burn achieved by shrinking overhead, while the balance sheet stays externally financed.
Between FY2023 and FY2025, revenue fell from$5.7M to$2.1M . Yet operating cash burn improved from-$4.1M to-$1.7M , showing a smaller cost base rather than fixed-cost absorption from growth.
In FY2025, SG&A was
The company remained funding-dependent: financing cash inflow of
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Healthlynked's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Healthlynked has an operating margin of -102.3%, meaning the company retains $-102 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -155.5% the prior year.
Healthlynked's revenue declined 31.3% year-over-year, from $3.0M to $2.1M. This contraction results in a growth score of 0/100.
Healthlynked has elevated debt relative to equity (D/E of -1.30), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 14/100, reflecting increased financial risk.
Healthlynked's current ratio of 0.22 is below the typical benchmark, resulting in a score of 0/100. This tight liquidity could limit financial flexibility if cash inflows slow.
Healthlynked passes 2 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
For every $1 of reported earnings, Healthlynked generates $0.52 in operating cash flow (-$1.7M OCF vs -$3.3M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Healthlynked generated $2.1M in revenue in fiscal year 2025. This represents a decrease of 31.3% from the prior year.
Healthlynked's EBITDA was -$2.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 54.2% from the prior year.
Healthlynked reported -$3.3M in net income in fiscal year 2025. This represents an increase of 46.5% from the prior year.
Healthlynked earned $-1.16 per diluted share (EPS) in fiscal year 2025. This represents an increase of 46.8% from the prior year.
Cash & Balance Sheet
Healthlynked held $37K in cash against $0 in long-term debt as of fiscal year 2025.
Healthlynked had 3M shares outstanding in fiscal year 2025. This represents an increase of 1.6% from the prior year.
Margins & Returns
Healthlynked's operating margin was -102.3% in fiscal year 2025, reflecting core business profitability. This is up 53.2 percentage points from the prior year.
Healthlynked's net profit margin was -158.8% in fiscal year 2025, showing the share of revenue converted to profit. This is up 45.0 percentage points from the prior year.
Capital Allocation
HLYK Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $423K+36.5% | $310K-20.2% | $389K-34.4% | $592K-23.5% | $774K+25.1% | $619K+4.9% | $590K-25.8% | $795K |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | $847K+86.8% | $454K-9.4% | $501K+10.8% | $452K-28.2% | $629K+15.2% | $546K-13.6% | $632K-26.7% | $861K |
| Operating Income | -$701K-32.0% | -$531K-0.2% | -$530K-21.6% | -$435K+29.5% | -$617K+17.5% | -$749K+55.2% | -$1.7M-54.8% | -$1.1M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$1.6M-139.7% | -$676K+20.6% | -$852K-21.5% | -$701K+33.3% | -$1.1M+14.6% | -$1.2M+37.7% | -$2.0M-28.1% | -$1.5M |
| EPS (Diluted) | $-0.56 | N/A | $-0.30 | $0.00 | $0.00 | N/A | $-0.70-6900.0% | $-0.01 |
HLYK Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.6M-4.5% | $1.7M-3.5% | $1.8M-4.5% | $1.8M-10.2% | $2.1M-7.5% | $2.2M-19.4% | $2.8M-28.5% | $3.9M |
| Current Assets | $1.5M-0.8% | $1.6M+0.6% | $1.5M-1.0% | $1.6M-0.5% | $1.6M-4.5% | $1.6M-10.0% | $1.8M-9.0% | $2.0M |
| Cash & Equivalents | $24K-35.4% | $37K+240.4% | $11K-46.0% | $20K-9.3% | $22K-70.8% | $76K+409.7% | $15K-91.3% | $173K |
| Inventory | $18K+2.8% | $18K-43.8% | $32K+15.9% | $28K-14.5% | $32K-27.8% | $45K-43.3% | $79K-18.3% | $96K |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | $26K-33.7% | $39K |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $8.6M+15.9% | $7.5M+3.7% | $7.2M+9.0% | $6.6M+6.6% | $6.2M+15.7% | $5.4M+14.1% | $4.7M+9.5% | $4.3M |
| Current Liabilities | $8.2M+16.9% | $7.0M+4.0% | $6.7M+10.1% | $6.1M+9.4% | $5.6M+19.4% | $4.7M+23.2% | $3.8M+12.1% | $3.4M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$7.0M-21.9% | -$5.8M-6.0% | -$5.4M-14.3% | -$4.8M-14.9% | -$4.1M-32.2% | -$3.1M-61.9% | -$1.9M-355.3% | -$425K |
| Retained Earnings | -$52.2M-3.3% | -$50.5M+0.5% | -$50.8M-1.7% | -$49.9M-1.4% | -$49.2M-2.2% | -$48.2M-2.6% | -$46.9M-4.4% | -$45.0M |
HLYK Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$222K+47.1% | -$419K+5.6% | -$444K-6.4% | -$418K+3.5% | -$433K+41.8% | -$744K+28.3% | -$1.0M-20.8% | -$859K |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | $0 | $0 | $0 |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | -$744K+28.3% | -$1.0M-20.8% | -$859K |
| Investing Cash Flow | N/A | N/A | N/A | N/A | N/A | $425K | $0 | $0 |
| Financing Cash Flow | $209K-34.9% | $321K-26.3% | $435K+4.7% | $415K+9.7% | $379K-0.3% | $380K-56.8% | $879K-12.8% | $1.0M |
| Dividends Paid | $36K | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
HLYK Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -165.5%+5.7pp | -171.2%-34.9pp | -136.3%-62.8pp | -73.5%+6.2pp | -79.7%+41.2pp | -121.0%+162.2pp | -283.2%-147.4pp | -135.8% |
| Net Margin | -382.9%-164.8pp | -218.1%+1.1pp | -219.2%-100.9pp | -118.3%+17.4pp | -135.7%+63.0pp | -198.8%+135.6pp | -334.4%-140.6pp | -193.8% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -99.7%-60.0pp | -39.7%+8.5pp | -48.3%-10.3pp | -37.9%+13.2pp | -51.1%+4.3pp | -55.3%+16.2pp | -71.5%-31.6pp | -39.9% |
| Current Ratio | 0.19-0.0 | 0.220.0 | 0.23-0.0 | 0.25-0.0 | 0.28-0.1 | 0.35-0.1 | 0.48-0.1 | 0.59 |
| Debt-to-Equity | -1.23+0.1 | -1.30+0.0 | -1.32+0.1 | -1.39+0.1 | -1.50+0.2 | -1.71+0.7 | -2.43+7.7 | -10.09 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | -120.1%+55.6pp | -175.7%-67.7pp | -108.0% |
Note: Shareholder equity is negative (-$5.8M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.22), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
What is Healthlynked's annual revenue?
Healthlynked (HLYK) reported $2.1M in total revenue for fiscal year 2025. This represents a -31.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Healthlynked's revenue growing?
Healthlynked (HLYK) revenue declined by 31.3% year-over-year, from $3.0M to $2.1M in fiscal year 2025.
Is Healthlynked profitable?
No, Healthlynked (HLYK) reported a net income of -$3.3M in fiscal year 2025, with a net profit margin of -158.8%.
What is Healthlynked's EBITDA?
Healthlynked (HLYK) had EBITDA of -$2.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Healthlynked's operating margin?
Healthlynked (HLYK) had an operating margin of -102.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Healthlynked's net profit margin?
Healthlynked (HLYK) had a net profit margin of -158.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Healthlynked's operating cash flow?
Healthlynked (HLYK) generated -$1.7M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Healthlynked's total assets?
Healthlynked (HLYK) had $1.7M in total assets as of fiscal year 2025, including both current and long-term assets.
What is Healthlynked's current ratio?
Healthlynked (HLYK) had a current ratio of 0.22 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Healthlynked's debt-to-equity ratio?
Healthlynked (HLYK) had a debt-to-equity ratio of -1.30 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Healthlynked's return on assets (ROA)?
Healthlynked (HLYK) had a return on assets of -192.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Healthlynked's cash runway?
Based on fiscal year 2025 data, Healthlynked (HLYK) had $37K in cash against an annual operating cash burn of $1.7M. This gives an estimated cash runway of approximately 0 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Healthlynked's debt-to-equity ratio negative or unusual?
Healthlynked (HLYK) has negative shareholder equity of -$5.8M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Healthlynked's Piotroski F-Score?
Healthlynked (HLYK) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Healthlynked's earnings high quality?
Healthlynked (HLYK) has an earnings quality ratio of 0.52x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Healthlynked?
Healthlynked (HLYK) scores 2 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.